FAPI-PET predicts treatment response in patients with rheumatoid arthritis
In this study, they further analyzed data from 19 patients to determine whether FAPI-PET could help predict treatment responses.
All of the patients had high or moderate disease activity and underwent PET/CT exams at baseline, as well as standard F-18 FDG PET/CT scans for comparison. Subsequent treatments included conventional DMARDs (including methotrexate, leflunomide, cyclophosphamide, and tripterygium wilfordii), and synthetic DMARDs (including etanercept, adalimumab, and Janus Kinase inhibitors). Six patients received additional prednisone, and six patients had nonsteroidal anti-inflammatory drugs.Representative Ga-6...
Source: AuntMinnie.com Headlines - January 9, 2024 Category: Radiology Authors: Will Morton Tags: Subspecialties Nuclear Radiology Source Type: news
Relationship between falls and the use of hypnotics, antidepressants, antipsychotics, and anxiolytics in patients with rheumatoid arthritis: a cross-sectional study - Sakurai K, Yanai R, Isozaki T, Yajima N.
OBJECTIVEs This cross-sectional study aimed to determine the relationship between falls and use of psychotropic medications in patients with rheumatoid arthritis. METHODS The psychotropic medication group included patients with rheumatoid arthritis... (Source: SafetyLit)
Source: SafetyLit - January 1, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Disease-Modifying Antirheumatic Drugs May Cut Incidence of Autoimmune Thyroid Disease
WEDNESDAY, Dec. 27, 2023 -- Disease-modifying antirheumatic drugs (DMARDs) might prevent incidence of autoimmune thyroid disease (AITD) in patients with rheumatoid arthritis (RA), according to a study recently published in the Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2023 Category: Pharmaceuticals Source Type: news
The Most Exciting New Advancements in Managing and Treating Lupus
The case study involved just one patient: a 20-year-old woman with severe systemic lupus erythematosus (SLE). But the study’s results were so dramatic that they appeared in 2021 in the New England Journal of Medicine.
The woman received a type of cell therapy called CAR-T, which in the past has been used primarily to treat cancer. CAR-T cell therapy involves altering a patient’s immune cells so that they identify and attack problems or pathogens. In people with cancer, that attack is aimed at the diseased cells. But in the NEJM case study, the therapy was directed at the woman’s own B cells,...
Source: TIME: Health - December 27, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
A New Test Could Save Arthritis Patients Time, Money, and Pain
(MedPage Today) -- SAN DIEGO -- Erinn Maury, MD, knew infliximab (Remicade) wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - December 23, 2023 Category: Rheumatology Source Type: news
Biocon Biologics grants Sandoz exclusive rights to market biosimilar adalimumab in Japan
Adalimumab BS for subcutaneous injection is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 22, 2023 Category: Pharmaceuticals Source Type: news
This Program Helped Overweight RA Patients Shape Up
(MedPage Today) -- In older overweight individuals with rheumatoid arthritis (RA), a composite of metabolic biomarkers as well as disease activity measures improved substantially with a professionally directed diet and home-exercise regimen, researchers... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 22, 2023 Category: Primary Care Source Type: news
Frailty Worsens Side Effects of Rheumatoid Arthritis Treatment
(MedPage Today) -- Patients starting targeted therapies for rheumatoid arthritis (RA) were more likely to develop serious infections and other adverse events if they were considered frail, insurance claims data indicated.
Rates of serious infections... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 21, 2023 Category: Primary Care Source Type: news
A New Test Could Save Arthritis Patients Time, Money, Pain A New Test Could Save Arthritis Patients Time, Money, Pain
Stories of chronic pain, drug-hopping, and insurance meddling are all too common among patients with rheumatoid arthritis. Precision medicine offers new hope.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2023 Category: Consumer Health News Tags: Rheumatology Source Type: news
Main Line biopharmaceutical firm to cut workforce by nearly half
The move comes about a month after the company halted development of its experimental rheumatoid arthritis drug. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 20, 2023 Category: Pharmaceuticals Authors: John George Source Type: news
New procedure shows promise reducing knee osteoarthritis pain
Genicular artery embolization can improve pain and knee function for at least three months in patients with knee osteoarthritis, according to a study published on December 15 in Diagnostic and Interventional Imaging.The finding comes from a first-in-human trial of genicular artery embolization (GAE) using an ethiodized oil-based emulsion for the temporary treatment of knee osteoarthritis, and it suggests that the technique is safe for pain management in patients who are not candidates for surgery, the researchers noted.“GAE using an ethiodized oil-based emulsion is safe and improves pain and function in participants with...
Source: AuntMinnie.com Headlines - December 20, 2023 Category: Radiology Authors: Will Morton Tags: Digital X-Ray Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Media News - December 19, 2023 Category: Pharmaceuticals Source Type: news
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study showed Xolair significantly increased the amount of peanut, milk, egg and cashew it took to cause an allergic reaction17 million people in the U.S. have confirmed food allergies and more than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2,3Basel, 19 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration ...
Source: Roche Investor Update - December 19, 2023 Category: Pharmaceuticals Source Type: news
Rheumatoid Arthritis Drug Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 -- A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes.Australian researchers report that baricitinib (Olumiant) appears to help patients newly diagnosed with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2023 Category: General Medicine Source Type: news
Rheumatoid Arthritis Drug, Baricitinib (Olumiant), Could Put Brakes on Type 1 Diabetes
THURSDAY, Dec. 7, 2023 -- A drug long used to curb rheumatoid arthritis may be a potent foe against another immune disorder, type 1 diabetes.
Australian researchers report that baricitinib (Olumiant) appears to help patients newly diagnosed with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 7, 2023 Category: General Medicine Source Type: news
